Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback